Abstract Library

#3228 Sensitivity of 68Ga-DOTATATE PET in detecting primary tumor and nodal metastases in surgically resected lung carcinoids

Introduction: 68Ga-DOTATATE positron emission tomography (PET) is increasingly employed in staging of lung carcinoids prior to surgery.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Rakshit S

Authors: Rakshit S, Lee K, Kendi A, Wigle D, Leventakos K,

Keywords: DOTATATE PET, staging, carcinoid,

#2938 Rectal Neuroendocrine Tumor with Concomitant Erdheim-Chester Disease: A Rare Case Report

Introduction: Rectal neuroendocrine tumor (NET), a type of rare tumor, is rather rarer when accompanied by non-Langerhans cells histiocytosis named Erdheim-Chester disease (ECD).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Zhang Y, Liu M, Chen L, Guo Y, Chen M,

Keywords: rectal neuroendocrine tumor, Erdheim-Chester disease.,

#2888 Progression-Free Survival as a Surrogate Endpoint in Gastroenteropancreatic Neuroendocrine Tumors Treated with Somatostatin Analogues

Introduction: Progression-free survival (PFS) has been used as surrogate endpoint in phase III trials with somatostatin analogues for gastroentero-pancreatic neuroendocrine tumors (GEP-NET). However, this endpoint has not been validated in this scenario.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Jimenez Fonseca P

Authors: Jimenez-Fonseca P, Carmona-Bayonas A, Lamarca A, Barriuso J, Castaño A,

Keywords: somatostatin analogues, surrogate, PFS, OS, correlation, kendall,

#495 Risk Factors for Sporadic Pancreatic Neuroendocrine Tumors (PNETs): Updated Results From a Single-Center Case Control Study

Introduction: PNETs are uncommon and little is known about risk factors and association with other cancers.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Halfdanarson T, Bamlet W, McWilliams R, Hobday T, Burch P,

Keywords: pancreatic neuroendocrine tumors, risk factors,

#386 A Prospective Evaluation of the Effects of Chronic Proton Pump Inhibitor Use on Plasma Biomarker Levels in Humans

Introduction: Proton pump inhibitors (PPIs) are used primarily to treat gastroesophageal reflux disease. PPI-induced achlorhydria increases circulating gastrin and chromogranin A (CGA). CGA is a widely used biomarker for the diagnosis and follow-up for gut-based neuroendocrine tumors (NETs). PPI-induced increases in CGA or gastrin may falsely suggest the presence of a NET when none exists. Pancreastatin, a fragment of CGA, is also commonly used to diagnose and follow NETs.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Raines D, Chester M, Diebold A, Mamikunian P, Anthony C,

Keywords: Chromogranin A, gastrin, pancreastatin, neuroendocrine tumor (NET),